New drug with immunotherapy for extensive-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This study tests a new drug (ZL-1310) combined with immunotherapy for people with extensive-stage small cell lung cancer who have not had prior treatment. It compares this new combination to the standard first-line treatment (chemotherapy plus immunotherapy).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have extensive-stage small cell lung cancer (cancer that has spread beyond the lung and nearby lymph nodes).
- You must not have received any prior treatment for your lung cancer (this is your first therapy).
- You must be healthy enough to receive standard chemotherapy with a checkpoint inhibitor (a type of immunotherapy).
- You must be fully active or able to do light work (performance status of 0 or 1).
- Your doctor expects you to live at least 3 months.
- Your major organs and bone marrow must be functioning adequately.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new combination of two drugs (QLC5508 and QL2107) compared to the standard treatment (tislelizumab plus chemotherapy) for people with extensive-stage small cell lung cancer who have not yet received treatment. The goal is to see if the new combination works better at controlling the cancer.
This trial tests a new combination of drugs (I-DXd and atezolizumab, with or without carboplatin) as your first treatment for extensive stage small cell lung cancer. It has two groups: one for people who haven't started treatment yet, and another for those who've already had 4 cycles of a standard chemo-immunotherapy combination and are stable or better.
This study tests whether adding radiation therapy to the chest after initial chemotherapy and immunotherapy can help keep extensive stage small cell lung cancer under control longer. It is designed for people whose cancer responded well to the first round of treatment.
This trial tests an investigational drug called BNT327, given with standard chemotherapy, for people newly diagnosed with extensive-stage small cell lung cancer. The goal is to see if adding this drug improves outcomes compared to chemotherapy alone.
This trial tests a combination of two drugs—lurbinectedin and durvalumab—for people with extensive-stage small cell lung cancer who have already received initial treatment. The goal is to see if this combination can help control the cancer better.
This trial tests a new drug called ZL-1310, alone or with other treatments, for people with small cell lung cancer that has spread (extensive-stage). It aims to see if ZL-1310 can help shrink tumors or slow the disease.
Hear when a new Small Cell Lung Cancer Extensive Stage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.